Ekaterina Legchenko
A5063050301- Pulmonary Hypertension Research and Treatments
- SARS-CoV-2 and COVID-19 Research
- Cardiovascular Function and Risk Factors
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Liver Disease Diagnosis and Treatment
- COVID-19 epidemiological studies
- Liver Disease and Transplantation
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- COVID-19 Pandemic Impacts
- Circular RNAs in diseases
- Congenital Heart Disease Studies
- Animal Virus Infections Studies
- Cardiovascular Issues in Pregnancy
- Galectins and Cancer Biology
- Viral gastroenteritis research and epidemiology
- Long-Term Effects of COVID-19
- Sulfur Compounds in Biology
- Cardiac Fibrosis and Remodeling
- COVID-19 and healthcare impacts
- Apelin-related biomedical research
- Chronic Obstructive Pulmonary Disease (COPD) Research
Medizinische Hochschule Hannover
2016-2025
University Medical Centre Mannheim
2025
Medizinische Fakultät Mannheim
2025
Heidelberg University
2025
University Hospital Heidelberg
2025
Papworth Hospital
2024
University of Cambridge
2020-2022
University College London
2021-2022
Pulmonary Vascular Research Institute
2019
Physico-Technical Institute
2014
Abstract The SARS-CoV-2 Omicron BA.1 variant emerged in 2021 1 and has multiple mutations its spike protein 2 . Here we show that the of a higher affinity for ACE2 compared with Delta, marked change antigenicity increases Omicron’s evasion therapeutic monoclonal vaccine-elicited polyclonal neutralizing antibodies after two doses. mRNA vaccination as third vaccine dose rescues broadens neutralization. Importantly, antiviral drugs remdesivir molnupiravir retain efficacy against BA.1....
Abstract Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy variants of concern (VOC) in individuals above eighty years age 1 . Here we analysed immune responses following with the BNT162b2 2 elderly participants and younger healthcare workers. Serum neutralization levels binding IgG or IgA after first dose were lower older individuals, a marked drop over old. Sera from showed potency B.1.1.7 (Alpha),...
Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3 week period (April 2020), 1032 HCWs were screened for large UK teaching hospital. Symptomatic staff household contacts additionally tested. Real-time RT-PCR was used to detect viral RNA from throat+nose self-swab. 3% group tested positive SARS-CoV-2. 17/30 (57%) truly...
Oral pioglitazone reverses pulmonary hypertensive vascular disease and prevents right heart failure via epigenetic, transcriptional, metabolic mechanisms.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike N-terminal domain (NTD) remains poorly characterized despite enrichment of mutations in this region across variants concern (VOCs). Here, we examine the contribution NTD to infection and cell-cell fusion by constructing chimeric spikes bearing B.1.617 lineage (Delta Kappa variants) NTDs generating pseudotyped lentivirus. We find that Delta on a or wild-type (WT) background increases S1/S2 cleavage efficiency virus entry,...
Potential loss-of-function variants of ATP13A3, the gene encoding a P5B-type transport ATPase undefined function, were recently identified in patients with pulmonary arterial hypertension (PAH). ATP13A3 is implicated polyamine but its function has not been fully elucidated. In this study, we sought to determine biological vascular endothelial cells (ECs) and how PAH-associated may contribute disease pathogenesis.
<h3>Background</h3> Several studies have identified circulating biomarkers to be associated with the presence and severity of pulmonary arterial hypertension (PAH). Recent evidence supports a role for galectin-3 (Gal-3) mineralcorticoid aldosterone in left ventricular failure. However, on together Gal-3 PAH are lacking. <h3>Objective</h3> We investigated novel Aldosterone-galectin-3 tandem several other potential their association disease severity. <h3>Methods</h3> A total 57 patients, 41...
Myocardial ischemia is one of the leading health problems worldwide. Therapy consists restitution coronary perfusion which followed by myocardial inflammation. Platelet-neutrophil interaction a crucial process during inflammation, yet its consequences are not fully understood. Here, we show that platelet-neutrophil complexes (PNCs) increased in patients with acute infarction and this associated levels neuronal guidance protein semaphorin 7A (SEMA7A). To investigate further, injected WT...
Inhaled pharmacotherapies are promising treatment options for patients with pulmonary arterial hypertension (PAH) as they minimize extrapulmonary adverse effects. Recently, we developed a highly specific inhibitor (TPHi) of the serotonin synthesizing enzyme tryptophan hydroxylase 1, TPT-004. We hypothesized that repetitive nose-only inhalation TPT-004 alleviates PAH and vascular remodeling in Sugen-hypoxia (SuHx) rat model. Male Sprague-Dawley rats were divided into 3 groups: (i) ConNx,...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of disease 2019 (COVID-19), has caused widespread morbidity and mortality since its onset in late 2019. Here, we demonstrate that prior infection with human cytomegalovirus (HCMV) substantially increases SARS-CoV-2 vitro. HCMV is a common herpesvirus carried by 40%-100% population, which can reactivate lung under inflammatory conditions, such as those resulting from infection. We show both endothelial...
We investigated whether concentrations of circulating microRNAs differ across the hypertensive right ventricle and pulmonary circulation, correlate with hemodynamic/echocardiographic variables in patients arterial hypertension versus nonpulmonary controls.Prospective blood collection during cardiac catheterization from superior vena cava, artery, ascending aorta 12 children nine matched controls, followed by an unbiased quantitative polymerase chain reaction array screen for 754...
The serotonin pathway has long been proposed as a promising target for pulmonary arterial hypertension (PAH)-a progressive and uncurable disease. We developed highly specific inhibitor of the synthesizing enzyme tryptophan hydroxylase 1 (TPH1), TPT-001 (TPHi). In this study, authors sought to treat severe PAH in Sugen/hypoxia (SuHx) rat model with oral TPHi TPT-001. Male Sprague Dawley rats were divided into 3 groups: 1) ConNx, control animals; 2) SuHx, injected subcutaneously SU5416 exposed...
Here we report application of human umbilical cord mesenchymal stem cell (HUCMSC)-derived therapy for pulmonary arterial hypertension (PAH). A 3-year-old female presented with heritable PAH associated hereditary hemorrhagic telangiectasia and was treated 6 months serial intravascular infusions conditioned media (CM) from allogenic HUCMSCs. The treatment markedly improved clinical hemodynamic parameters decreased blood plasma markers vascular fibrosis, injury inflammation. comparative...
Hepatic congestion occurs in patients with right heart failure and can ultimately lead to liver fibrosis or cardiac cirrhosis. Elevated pulmonary arterial pressure is found hepatic congestion. However, whether hypertension (PAH) be a cause of unknown. The aim this study was investigate rats the SuHx model severe PAH develop explore mechanisms congestive both humans. To achieve this, induced six eight-week old male Sprague Dawley by single subcutaneous injection VEGFR 2 inhibitor SU5416...